<p>Abiraterone Acetate is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with</p>

<ul>
	<li>Metastatic castration-resistant prostate cancer (CRPC)</li>
	<li>Metastatic high-risk castration-sensitive prostate cancer (CSPC)</li>
</ul>